---
title: "Genenta Science Regains Compliance with Nasdaq Minimum Bid Price Rule"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289933040.md"
description: "Genenta Science S.p.A. (GNTA) regained compliance with Nasdaq's minimum bid price rule after its shares closed at or above $1.00 from June 1-12, 2026. This resolves the non-compliance issue disclosed in April and eliminates the immediate risk of delisting from the Nasdaq Capital Market. The company, a biotechnology firm focused on gene therapies, currently has an average trading volume of over 1.4 million shares and a market cap of $43.82M."
datetime: "2026-06-16T14:01:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289933040.md)
  - [en](https://longbridge.com/en/news/289933040.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289933040.md)
generator: "portal-rs"
---

# Genenta Science Regains Compliance with Nasdaq Minimum Bid Price Rule

Genenta Science SpA Sponsored ADR ( (GNTA) ) has shared an update.

On June 15, 2026, Genenta Science S.p.A. announced that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing. Nasdaq confirmed that from June 1 through June 12, 2026, the company’s American Depositary Shares closed at or above this threshold, resolving the earlier non-compliance issue disclosed in April and closing the matter.

This return to compliance removes the immediate risk of potential delisting from the Nasdaq Capital Market, stabilizing Genenta’s U.S. trading status and helping preserve market confidence. The development supports continued access to public equity investors and may ease concerns among shareholders about trading liquidity and regulatory standing following the prior bid-price deficiency. 

The most recent analyst rating on (GNTA) stock is a Buy  
 with a $7.00 price target.  
 To see the full list of analyst forecasts on Genenta Science SpA Sponsored ADR stock,  
 see the GNTA Stock Forecast page. 

**More about Genenta Science SpA Sponsored ADR**

Genenta Science S.p.A. is a biotechnology company focused on developing gene therapies, with its American Depositary Shares listed on the Nasdaq Capital Market. The company operates in highly regulated U.S. capital markets, where maintaining listing standards such as minimum bid price requirements is critical for investor access and liquidity.

**Average Trading Volume:** 1,415,280

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $43.82M

### Related Stocks

- [GNTA.US](https://longbridge.com/en/quote/GNTA.US.md)

## Related News & Research

- [Tomra reschedules Capital Markets Day 2026 update for investors and analysts](https://longbridge.com/en/news/296784355.md)
- [BMO Capital Markets Upgrades Exelixis (NASDAQ:EXEL) to "Hold"](https://longbridge.com/en/news/296478537.md)
- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)
- [BullFrog AI gets Nasdaq extension to regain $1 minimum bid compliance, avoids delisting until Feb. 8, 2027](https://longbridge.com/en/news/296495894.md)
- [Brookline Capital Markets Comments on Oncobiologics Q1 Earnings](https://longbridge.com/en/news/296480549.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**